What is ADAKVEO® used for?1

ADAKVEO® (crizanlizumab) is used to prevent recurrent painful crises occurring in patients aged 16 and over with an inherited blood disorder called sickle cell disease (SCD).

SCD causes the affected red blood cells to become sickle-shaped and may have difficulty passing through small blood vessels and can result in a painful crisis.

Additionally, in SCD, blood vessels are damaged and sticky due to ongoing inflammation. This leads to blood cells sticking to the blood vessels, causing these acute painful crises (known as vaso-occlusive crises or VOCs) and organ damage. SCD patients also have higher levels of a protein called P-selectin, which is linked to VOCs.

 

How does ADAKVEO® work?1

ADAKVEO® contains the active substance crizanlizumab, which belongs to a group of medicines called monoclonal antibodies (mAbs), it binds P-selectin, which should stop blood cells sticking to the vessel walls, improving blood flow and helps to prevent VOCs and can be given in combination with hydroxyurea/hydroxycarbamide, although it may also be used alone.

 

More information

For more information about ADAKVEO® please consult:

Patient information leaflet (PIL) for ADAKVEO®

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Summary of Product Characteristics (SmPC) for ADAKVEO®

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

Abbreviations: SCD: sickle cell disease; VOC: vaso-occlusive crisis; mAbs: monoclonal antibodies.

Reference

  1. Summary of Product Characteristics(SmPC)for ADAKVEO®

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

Rate this content: 
No votes yet
UK | June 2022 | 211896
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.